Array BioPharma Inc

Find Ratings Reports
ARRY : NASDAQ : Health Care
$3.65 | %
Today's Range: 3.63 - 3.74
Avg. Daily Volume: 1,968,500
09/23/16 - 4:00 PM ET

Financial Analysis


ARRAY BIOPHARMA INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ARRAY BIOPHARMA INC is extremely liquid. Currently, the Quick Ratio is 2.85 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 188.93% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)43.2112.32
EBITDA ($mil)-22.06-20.72
EBIT ($mil)-22.31-21.64
Net Income ($mil)-25.01-12.73


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)109.94178.33
Total Assets ($mil)168.9198.21
Total Debt ($mil)113.66107.28
Equity ($mil)-37.9342.65


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin87.9850.88
EBITDA Margin-51.05-168.16
Operating Margin-51.63-175.68
Sales Turnover0.820.67
Return on Assets-54.964.72
Return on Equity0.021.96
Debt Q4 FY16 Q4 FY15
Current Ratio2.964.5
Debt/Capital1.50.72
Interest Expense2.782.62
Interest Coverage-8.02-8.27


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)143.69142.11
Div / share0.00.0
EPS-0.17-0.09
Book value / share-0.260.3
Institutional Own % n/a n/a
Avg Daily Volume1944093.01927706.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ARRY NM Peers 42.78   ARRY NM Peers 21.27

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ARRY's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ARRY's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ARRY NM Peers 31.52   ARRY NA Peers 0.49

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

ARRY's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ARRY NM Peers 10.46   ARRY -6600.00 Peers 1.93

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ARRY's P/B is negative making this valuation measure meaningless.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, ARRY is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ARRY 3.66 Peers 690.55   ARRY 4.51 Peers 51.56

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ARRY is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ARRY significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades